Top 10 AI Trending News on Wall Street

4. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Number of Hedge Fund Holders: 34

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics. On March 3, the company announced a strategic collaboration with ATTMOS to build a physics-based computational small molecule discovery platform.

The strategic partnership seeks to engineer and optimize a workflow solution to enhance the development of first-in-class drug candidate molecules. IDEAYA Biosciences, Inc.’s (NASDAQ:IDYA) partnership with ATTMOS represents a substantial technological advancement in enhancing AI-driven drug discovery capabilities. The partnership will combine ATTMOS’s software development and high-performance computing strengths with IDEAYA’s unique and demonstrated structural biology capabilities.

“Current AI/ML-enabled drug discovery approaches have been largely applied to either already drugged targets or well-understood biological target classes and often fail when applied to first-in-class target opportunities. IDEAYA continues to enhance its computational drug discovery capabilities to pursue first-in-class oncology targets that are perceived as undruggable,” said Michael White, Ph.D., Chief Scientific Officer, and IDEAYA Biosciences.”